Physicians' Academy for Cardiovascular Education

Another PCSK9 inhibitor safely reduces MACE in long term outcomes trial in high-risk patients

The ODYSSEY OUTCOMES Trial: Topline Results - Alirocumab in Patients After Acute Coronary Syndrome

Presented at ACC.18 by Ph. Gabriel Steg (Paris, France)

News - Mar. 9, 2018

Main results


These results of the ODYSSEY OUTCOMES study show that compared with placebo, in patients with recent ACS, alirocumab 75 or 150 mg Q2W reduced the primary endpoint of MACE. Moreover, a secondary analysis showed that alirocumab treatment was associated with a lower rate of all-cause death. Treatment with this PCSK9 inhibitor was safe and well tolerated over the duration of the trial.


Our coverage of ACC.18 is based on the information provided during the congress.

Share this page with your colleagues and friends: